Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics

被引:154
作者
Fattet, Sarah [2 ,3 ]
Haberler, Christine [2 ,4 ]
Legoix, Patricia [5 ]
Varlet, Pascale [6 ]
Lellouch-Tubiana, Arielle [7 ,8 ]
Lair, Severine [9 ,10 ]
Manie, Elodie [2 ]
Raquin, Marie-Anne [11 ]
Bours, Danielle
Carpentier, Sabrina [9 ,10 ]
Barillot, Emmanuel [9 ,10 ]
Grill, Jacques [11 ]
Doz, Francois [7 ,12 ]
Puget, Stephanie [8 ]
Janoueix-Lerosey, Isabelle [2 ]
Delattre, Olivier [1 ,2 ]
机构
[1] Inst Curie, INSERM, Ctr Rech, U830, F-75248 Paris 05, France
[2] INSERM, Lab Genet & Biol Canc, U830, F-75248 Paris 05, France
[3] CHU Vaudois, CH-1011 Lausanne, Switzerland
[4] Med Univ Vienna, Inst Neurol, A-1097 Vienna, Austria
[5] Inst Curie, Dept Transfert, F-75248 Paris 05, France
[6] Ctr Hosp St Anne, Neuropathol Lab, F-75014 Paris, France
[7] Univ Paris 05, Fac Med, F-75006 Paris, France
[8] Hop Necker Enfants Malad, F-75015 Paris, France
[9] INSERM, U900, F-75248 Paris 05, France
[10] Ecole Mines ParisTech, F-77300 Fontainebleau, France
[11] Inst Gustave Roussy, F-94805 Villejuif, France
[12] Inst Curie, F-75005 Paris, France
基金
奥地利科学基金会;
关键词
medulloblastoma; CTNNB1; mutation; beta-catenin; chromosome; 6; deletion; array CGH; expression profile; immunocytochemistry; survival; neoplasia; STANDARD-RISK MEDULLOBLASTOMA; CHILDHOOD MEDULLOBLASTOMA; PROGNOSTIC-FACTORS; TUMOR; CHEMOTHERAPY; CHILDREN; PATHWAY; STRATIFICATION; RADIOTHERAPY; PREDICTS;
D O I
10.1002/path.2514
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Medulloblastoma is the most frequent malignant paediatric brain tumour. The activation of the Wnt/beta-catenin pathway occurs in 10-15% of medulloblastomas and has been recently described as a marker for favourable patient outcome. We report a series of 72 paediatric medulloblastomas evaluated for beta-catenin protein expression, CTNNB1 mutations, and comparative genomic hybridization. Gene expression profiles were also available in a subset of 40 cases. Immunostaining of beta-catenin showed extensive nuclear staining (>50% of the tumour cells) in six cases and focal nuclear staining (<10 % of cells) in three cases. The other cases either exhibited a signal strictly limited to the cytoplasm (58 cases) or were negative (five cases). CTNNB1 mutations were detected in all beta-catenin extensively nucleopositive cases. The expression profiles of these cases documented strong activation of the Wnt/beta-catenin pathway. Remarkably, five out of these six tumours showed a complete loss of chromosome 6. In contrast, cases with focal nuclear beta-catenin staining, as well as tumours with negative or cytoplasmic staining, never demonstrated CTNNB1 mutation, Wnt/beta-catenin pathway activation or chromosome 6 loss. Patients with extensive nuclear staining were significantly older at diagnosis and were in continuous complete remission after a mean follow-up of 75.7 months (range 27.5-121.2 months) from diagnosis. All three patients with focal nuclear staining of beta-catenin died within 36 months from diagnosis. Altogether, these data confirm and extend previous observations that CTNNB1-mutated tumours represent a distinct molecular subgroup of medulloblastomas with favourable outcome, indicating that therapy de-escalation should be considered. International consensus on the definition criteria of this distinct medulloblastoma subgroup should be achieved. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:86 / 94
页数:9
相关论文
共 35 条
[11]   Wnt signalling and the mechanistic basis of tumour development [J].
Ilyas, M .
JOURNAL OF PATHOLOGY, 2005, 205 (02) :130-144
[12]   Tumor formation by genetic mutations in the components of the Wnt signaling pathway [J].
Kikuchi, A .
CANCER SCIENCE, 2003, 94 (03) :225-229
[13]   Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features [J].
Kool, Marcel ;
Koster, Jan ;
Bunt, Jens ;
Hasselt, Nancy E. ;
Lakeman, Arjan ;
van Sluis, Peter ;
Troost, Dirk ;
Schouten-van Meeteren, Netteke ;
Caron, Huib N. ;
Cloos, Jacqueline ;
Mrsic, Alan ;
Ylstra, Bauke ;
Grajkowska, Wieslawa ;
Hartmann, Wolfgang ;
Pietsch, Torsten ;
Ellison, David ;
Clifford, Steven C. ;
Versteeg, Rogier .
PLOS ONE, 2008, 3 (08)
[14]   Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients [J].
Lamont, JM ;
McManamy, CS ;
Pearson, AD ;
Clifford, SC ;
Ellison, DW .
CLINICAL CANCER RESEARCH, 2004, 10 (16) :5482-5493
[15]   Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity [J].
Legoix, P ;
Bluteau, O ;
Bayer, J ;
Perret, C ;
Balabaud, C ;
Belghiti, J ;
Franco, D ;
Thomas, G ;
Laurent-Puig, P ;
Zucman-Rossi, J .
ONCOGENE, 1999, 18 (27) :4044-4046
[16]   The Wnt signaling pathway in development and disease [J].
Logan, CY ;
Nusse, R .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2004, 20 :781-810
[17]  
Louis DN., 2007, WHO CLASSIFICATION T
[18]   Nodule formation and desmoplasia in medulloblastomas - Defining the nodular/desmoplastic variant and its biological behavior [J].
McManamy, Charles S. ;
Pears, Jane ;
Weston, Claire L. ;
Hanzely, Zoltan ;
Ironside, James W. ;
Taylor, Roger E. ;
Grundy, Richard G. ;
Clifford, Steven C. ;
Ellison, David W. .
BRAIN PATHOLOGY, 2007, 17 (02) :151-164
[19]   Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas [J].
McManamy, CS ;
Lamont, JM ;
Taylor, RE ;
Cole, M ;
Pearson, ADJ ;
Clifford, SC ;
Ellison, DW .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2003, 62 (06) :627-632
[20]   Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor:: A SEER update [J].
McNeil, DE ;
Coté, TR ;
Clegg, L ;
Rorke, LB .
MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 39 (03) :190-194